The stock of Teligent Inc (NASDAQ:TLGT) is a huge mover today! The stock increased 4.83% or $0.35 during the last trading session, hitting $7.6. About 335,200 shares traded hands or 62.31% up from the average. Teligent Inc (NASDAQ:TLGT) has risen 16.56% since February 26, 2016 and is uptrending. It has outperformed by 6.13% the S&P500.
The move comes after 8 months positive chart setup for the $386.47 million company. It was reported on Sep, 30 by Barchart.com. We have $18.47 PT which if reached, will make NASDAQ:TLGT worth $552.65 million more.
Analysts await Teligent Inc (TLGT) to report earnings on October, 27. They expect $-0.01 earnings per share, up 50.00% or $0.01 from last year’s $-0.02 per share. After $0.01 actual earnings per share reported by Teligent Inc for the previous quarter, Wall Street now forecasts -200.00% negative EPS growth.
According to Zacks Investment Research, “Teligent, Inc. is a specialty generic pharmaceutical company, develops, manufactures and markets topical formulations primarily in the United States. It sells generic pharmaceutical products in topical, injectable, complex and ophthalmic dosage forms. Teligent Inc., formerly known as IGI Laboratories, Inc., is based in Buena, New Jersey.”
More notable recent Teligent Inc (NASDAQ:TLGT) news were published by: Prnewswire.com which released: “Teligent, Inc. To Present At Morgan Stanley Global Healthcare Conference On …” on September 13, 2016, also Marketwatch.com with their article: “Teligent Inc. NASDAQ: TLGT” published on October 29, 2015, Prnewswire.com published: “Teligent, Inc. Announces Health Canada Approval Of Gentamicin Injection USP” on August 23, 2016. More interesting news about Teligent Inc (NASDAQ:TLGT) were released by: Prnewswire.com and their article: “Teligent, Inc. Advances $50 Million Facility Expansion” published on July 06, 2016 as well as Fool.com‘s news article titled: “Why Teligent Inc. Plunged 18.5% in February” with publication date: March 07, 2016.
TLGT Company Profile
Teligent, Inc., formerly IGI Laboratories, Inc., incorporated on August 26, 1977, is a specialty generic pharmaceutical company. Under its own label, the Company markets and sells generic injectable pharmaceutical products in the United States and Canada. It is also marketing over eight generic topical pharmaceutical products and approximately four branded generic pharmaceutical products. The Firm provides development, formulation and manufacturing services to the pharmaceutical, over-the-counter (OTC) and cosmetic industries. The Firm focuses on developing, manufacturing and marketing a portfolio of generic pharmaceutical products under its own label in topical, injectable, complex and ophthalmic dosage forms, and managing its current contract manufacturing and formulation services business. The Company’s pipeline includes over 30 Abbreviated New Drug Applications (ANDAs) filed with the United States Food and Drug Administration (FDA) for additional pharmaceutical products. In addition, it has over four abbreviated new drug submissions (ANDS), on file with Health Canada. It holds additional over 40 product candidates at various stages of its development pipeline, approximately 10 of which are on stability testing.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.